Published in J Immunol on December 15, 1990
PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol (1999) 5.83
Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J (1998) 5.15
HSV-1 IE protein Vmw110 causes redistribution of PML. EMBO J (1994) 4.61
The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J (1994) 4.29
Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proc Natl Acad Sci U S A (2004) 4.19
The periphery of nuclear domain 10 (ND10) as site of DNA virus deposition. J Cell Biol (1996) 3.91
Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J Cell Biol (1997) 2.98
Targeting of adenovirus E1A and E4-ORF3 proteins to nuclear matrix-associated PML bodies. J Cell Biol (1995) 2.93
Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption. J Virol (1999) 2.87
TRIM proteins and cancer. Nat Rev Cancer (2011) 2.84
Interaction of SP100 with HP1 proteins: a link between the promyelocytic leukemia-associated nuclear bodies and the chromatin compartment. Proc Natl Acad Sci U S A (1998) 2.59
Sequestration and inhibition of Daxx-mediated transcriptional repression by PML. Mol Cell Biol (2000) 2.59
Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1997) 2.54
PML nuclear bodies. Cold Spring Harb Perspect Biol (2010) 2.44
Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein. J Virol (1998) 2.26
Disruption of PML subnuclear domains by the acidic IE1 protein of human cytomegalovirus is mediated through interaction with PML and may modulate a RING finger-dependent cryptic transactivator function of PML. Mol Cell Biol (1998) 2.21
An arenavirus RING (zinc-binding) protein binds the oncoprotein promyelocyte leukemia protein (PML) and relocates PML nuclear bodies to the cytoplasm. J Virol (1998) 2.20
Chromatin components as part of a putative transcriptional repressing complex. Proc Natl Acad Sci U S A (1998) 2.14
The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains. J Virol (1998) 2.12
Promyelocytic leukemia (PML) nuclear bodies are protein structures that do not accumulate RNA. J Cell Biol (2000) 2.11
Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J Virol (2001) 2.07
Molecular characterization of NDP52, a novel protein of the nuclear domain 10, which is redistributed upon virus infection and interferon treatment. J Cell Biol (1995) 1.92
Nuclear dot antigens may specify transcriptional domains in the nucleus. Mol Cell Biol (1993) 1.83
Evi9 encodes a novel zinc finger protein that physically interacts with BCL6, a known human B-cell proto-oncogene product. Mol Cell Biol (2000) 1.77
The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein. Mol Cell Biol (1998) 1.69
Two RING finger proteins, the oncoprotein PML and the arenavirus Z protein, colocalize with the nuclear fraction of the ribosomal P proteins. J Virol (1998) 1.64
Drosophila heterochromatin protein 1 (HP1)/origin recognition complex (ORC) protein is associated with HP1 and ORC and functions in heterochromatin-induced silencing. Mol Biol Cell (2001) 1.61
The transcription coactivator CBP is a dynamic component of the promyelocytic leukemia nuclear body. J Cell Biol (2001) 1.54
Sp110 localizes to the PML-Sp100 nuclear body and may function as a nuclear hormone receptor transcriptional coactivator. Mol Cell Biol (2000) 1.49
Lytic but not latent replication of epstein-barr virus is associated with PML and induces sequential release of nuclear domain 10 proteins. J Virol (2000) 1.47
Suppression of alternative lengthening of telomeres by Sp100-mediated sequestration of the MRE11/RAD50/NBS1 complex. Mol Cell Biol (2005) 1.44
The RNA 3' cleavage factors CstF 64 kDa and CPSF 100 kDa are concentrated in nuclear domains closely associated with coiled bodies and newly synthesized RNA. EMBO J (1996) 1.42
A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics. Int J Biol Sci (2010) 1.38
GATA transcription factors associate with a novel class of nuclear bodies in erythroblasts and megakaryocytes. EMBO J (1996) 1.32
Common properties of nuclear body protein SP100 and TIF1alpha chromatin factor: role of SUMO modification. Mol Cell Biol (2001) 1.29
SUMOylation of the human cytomegalovirus 72-kilodalton IE1 protein facilitates expression of the 86-kilodalton IE2 protein and promotes viral replication. J Virol (2004) 1.28
Mediation of Epstein-Barr virus EBNA-LP transcriptional coactivation by Sp100. EMBO J (2005) 1.28
Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains. EMBO J (1996) 1.27
PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol (1999) 1.25
Regulation of matrix attachment region-dependent, lymphocyte-restricted transcription through differential localization within promyelocytic leukemia nuclear bodies. EMBO J (2000) 1.19
Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut (1994) 1.18
The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies. J Cell Biol (2012) 1.17
H-1 parvovirus-associated replication bodies: a distinct virus-induced nuclear structure. J Virol (2000) 1.12
Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues. Am J Pathol (1996) 1.11
Sp100 interacts with ETS-1 and stimulates its transcriptional activity. Mol Cell Biol (2002) 1.11
Association of the neuron-specific RNA binding domain-containing protein ELAV with the coiled body in Drosophila neurons. Chromosoma (1997) 1.11
Human cytomegalovirus infection causes degradation of Sp100 proteins that suppress viral gene expression. J Virol (2011) 1.09
Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther (2011) 1.09
Components of nuclear domain 10 bodies regulate varicella-zoster virus replication. J Virol (2009) 1.07
Interplay between Herpesvirus Infection and Host Defense by PML Nuclear Bodies. Viruses (2009) 1.03
Cellular localization, expression, and structure of the nuclear dot protein 52. J Cell Biol (1997) 1.02
Structural and functional heterogeneity of nuclear bodies. Mol Cell Biol (1999) 1.02
Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci (2010) 1.01
Autoantibodies from patients with primary biliary cirrhosis recognize a restricted region within the cytoplasmic tail of nuclear pore membrane glycoprotein Gp210. J Exp Med (1993) 0.99
Nuclear DNA helicase II is recruited to IFN-alpha-activated transcription sites at PML nuclear bodies. J Cell Biol (2002) 0.97
Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays. Mol Cell Proteomics (2012) 0.96
The mouse Aire gene: comparative genomic sequencing, gene organization, and expression. Genome Res (1999) 0.94
Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol (2009) 0.93
A highly amplified mouse gene is homologous to the human interferon-responsive Sp100 gene encoding an autoantigen associated with nuclear dots. Mol Cell Biol (1996) 0.90
Sp100 isoform-specific regulation of human adenovirus 5 gene expression. J Virol (2014) 0.89
Autoantigens in primary biliary cirrhosis. J Clin Pathol (2000) 0.86
Epitope-specific anti-nuclear antibodies are expressed in a mouse model of primary biliary cirrhosis and are cytokine-dependent. Clin Exp Immunol (2012) 0.82
SUMO5, a Novel Poly-SUMO Isoform, Regulates PML Nuclear Bodies. Sci Rep (2016) 0.82
Characterization of genomic vitamin D receptor binding sites through chromatin looping and opening. PLoS One (2014) 0.81
Nuclear domain 10 of the viral aspect. World J Virol (2013) 0.80
Anti-multiple nuclear dots (anti-MND) and anti-SP100 antibodies in hepatic and rheumatological disorders. Clin Exp Immunol (2002) 0.79
PML plays both inimical and beneficial roles in HSV-1 replication. Proc Natl Acad Sci U S A (2016) 0.78
SP140L, an Evolutionarily Recent Member of the SP100 Family, Is an Autoantigen in Primary Biliary Cirrhosis. J Immunol Res (2015) 0.77
Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis. PLoS One (2014) 0.77
Antibodies to Ro/La, Cenp-B, and snRNPs antigens in autoimmune hepatitis of North America versus Asia: patterns of immunofluorescence, ELISA reactivities, and HLA association. Dig Dis Sci (1998) 0.76
Human promyelocytic leukemia protein is targeted to distinct subnuclear domains in plant nuclei and colocalizes with nucleolar constituents in a SUMO-dependent manner. FEBS Open Bio (2016) 0.76
Multifaceted Histone H3 Methylation and Phosphorylation Readout by the Plant Homeodomain Finger of Human Nuclear Antigen Sp100C. J Biol Chem (2016) 0.75
Two short autoepitopes on the nuclear dot antigen are similar to epitopes encoded by the Epstein-Barr virus. Proc Natl Acad Sci U S A (1995) 0.75
New nucleotide sequence data on the EMBL File Server. Nucleic Acids Res (1991) 0.75
A new sensitive method for qualitative and quantitative assay of neomycin phosphotransferase in crude cell extracts. Gene (1984) 7.36
Signals regulating hepatitis B surface antigen transcription. Nature (1983) 5.02
Comparative sequence analysis of duck and human hepatitis B virus genomes. J Med Virol (1985) 4.68
Replication strategy of human hepatitis B virus. J Virol (1987) 4.42
Transcripts and the putative RNA pregenome of duck hepatitis B virus: implications for reverse transcription. Cell (1985) 4.41
Modification of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICP0). J Gen Virol (1993) 4.32
Hepatitis B virus transcription in the infected liver. EMBO J (1984) 3.44
A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol (1995) 3.35
Isolation and characterization of a hepatitis B virus endemic in herons. J Virol (1988) 3.23
Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem (1996) 3.00
Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J Cell Biol (1997) 2.98
Cloned HBV DNA causes hepatitis in chimpanzees. Nature (1982) 2.80
Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology (2001) 2.71
The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem (1998) 2.71
Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem (1997) 2.63
Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J (2000) 2.38
IFN enhance expression of Sp100, an autoantigen in primary biliary cirrhosis. J Immunol (1992) 2.24
The nuclear dot protein sp100, characterization of domains necessary for dimerization, subcellular localization, and modification by small ubiquitin-like modifiers. J Biol Chem (1999) 2.21
Infectious hepatitis B virus from cloned DNA of known nucleotide sequence. Proc Natl Acad Sci U S A (1985) 2.20
Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A (1991) 2.05
Putative reverse transcriptase intermediates of human hepatitis B virus in primary liver carcinomas. Science (1986) 2.00
Monoclonal antibodies against chromosomal proteins of Drosophila melanogaster: establishment of antibody producing cell lines and partial characterization of corresponding antigens. Chromosoma (1980) 1.97
Expression of the hepatitis B virus core gene in vitro and in vivo. J Virol (1987) 1.96
The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity. J Virol (1992) 1.95
Cloned duck hepatitis B virus DNA is infectious in Pekin ducks. J Virol (1984) 1.80
Expression of hepatitis B antigens with a simian virus 40 vector. J Virol (1984) 1.80
Structure of human ferritin light subunit messenger RNA: comparison with heavy subunit message and functional implications. Proc Natl Acad Sci U S A (1985) 1.79
A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis. Hepatology (2001) 1.78
Human anti-centromere sera recognise a 19.5 kD non-histone chromosomal protein from HeLa cells. Clin Exp Immunol (1984) 1.78
Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier. Virology (1993) 1.75
Generation of stable mRNA fragments and translation of N-truncated proteins induced by antisense oligodeoxynucleotides. Mol Cell (2001) 1.74
Naturally occurring variants of hepatitis B virus. Adv Virus Res (1999) 1.72
Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol (1995) 1.71
Molecular biology of viral and nonviral retroelements. Trends Genet (1989) 1.65
Serological pattern "anti-HBc alone": report on a workshop. J Med Virol (2000) 1.65
Body language: the function of PML nuclear bodies in apoptosis regulation. Cell Death Differ (2003) 1.62
Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci U S A (1997) 1.60
Detection of an element of the SV40 late promoter in vectors used for expression studies in COS cells. EMBO J (1983) 1.57
Ribonucleoprotein complexes of hepatitis delta virus. J Virol (1993) 1.56
Interferon-modulated expression of genes encoding the nuclear-dot-associated proteins Sp100 and promyelocytic leukemia protein (PML). Eur J Biochem (1996) 1.50
The autoimmune regulator protein has transcriptional transactivating properties and interacts with the common coactivator CREB-binding protein. J Biol Chem (2000) 1.49
Identification of human Sm and (U1) RNP antigens by immunoblotting. J Immunol Methods (1983) 1.45
Nuclear dots: actors on many stages. Immunobiology (1997) 1.45
Heterogeneity and common features of defective hepatitis B virus genomes derived from spliced pregenomic RNA. Virology (1997) 1.42
A new avian hepadnavirus infecting snow geese (Anser caerulescens) produces a significant fraction of virions containing single-stranded DNA. Virology (1999) 1.38
Two nuclear dot-associated proteins, PML and Sp100, are often co-autoimmunogenic in patients with primary biliary cirrhosis. Scand J Immunol (1995) 1.36
Amplification of full-length hepatitis B virus genomes from samples from patients with low levels of viremia: frequency and functional consequences of PCR-introduced mutations. J Clin Microbiol (1998) 1.34
Epitope mapping with a recombinant human 68-kDa (U1) ribonucleoprotein antigen reveals heterogeneous autoantibody profiles in human autoimmune sera. J Immunol (1988) 1.34
Monoclonal antibody directed against RNA polymerase II of Drosophila melanogaster. Mol Gen Genet (1980) 1.33
Internal entry of ribosomes and ribosomal scanning involved in hepatitis B virus P gene expression. J Virol (1989) 1.31
Precore mutant hepatitis B virus infection and liver disease. Gastroenterology (1992) 1.31
Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I. Chromosoma (1986) 1.30
Hepatitis B virus nucleocapsid/pre-S2 fusion proteins expressed in attenuated Salmonella for oral vaccination. J Immunol (1990) 1.27
PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol (1999) 1.25
Identification and analysis of a new hepadnavirus in white storks. Virology (2001) 1.24
A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. J Hepatol (1990) 1.24
Effects of nucleotide changes on the ability of hepatitis delta virus to transcribe, process, and accumulate unit-length, circular RNA. J Virol (1997) 1.24
A recombinant Chinese hamster ovary cell line containing a 300-fold amplified tetramer of the hepatitis B genome together with a double selection marker expresses high levels of viral protein. J Mol Biol (1986) 1.23
Enhancement of hepatitis B virus infection by noninfectious subviral particles. J Virol (1998) 1.22
Isolation and characterization of the human hepatic lipase gene. J Biol Chem (1990) 1.22
Type, prevalence, and significance of core promoter/enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease. J Virol (1996) 1.21
Expression mechanism of the hepatitis B virus (HBV) C gene and biosynthesis of HBe antigen. Virology (1989) 1.21
A new hepatitis B virus variant in a chronic carrier with multiple episodes of viral reactivation and acute hepatitis. Virology (1990) 1.21
Full-length and truncated versions of the hepatitis B virus (HBV) X protein (pX) transactivate the cmyc protooncogene at the transcriptional level. Biochem Biophys Res Commun (1991) 1.20
The interferon (IFN)-stimulated gene Sp100 promoter contains an IFN-gamma activation site and an imperfect IFN-stimulated response element which mediate type I IFN inducibility. J Biol Chem (1996) 1.17
Membrane-type-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases. Eur J Biochem (1997) 1.16
Hepatitis B virus genomes that cannot synthesize pre-S2 proteins occur frequently and as dominant virus populations in chronic carriers in Italy. Virology (1992) 1.15
Introduction of hepatitis delta virus into animal cell lines via cationic liposomes. J Virol (1994) 1.15
Frequent and rapid emergence of mutated pre-C sequences in HBV from e-antigen positive carriers who seroconvert to anti-HBe during interferon treatment. Virology (1992) 1.15
Alterations in thyroid status modulate apolipoprotein, hepatic triglyceride lipase, and low density lipoprotein receptor in rats. Endocrinology (1990) 1.14
Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure. J Hepatol (1999) 1.14
Effect of interferon alpha on hepatitis B virus replication and gene expression in transiently transfected human hepatoma cells. J Hepatol (1999) 1.13
Potent inhibition of hepatitis B virus production in vitro by modified pyrimidine nucleosides. Antimicrob Agents Chemother (1990) 1.12
A recombinant autoantigen derived from the human (U1) small nuclear RNP-specific 68-kd protein. Expression in Escherichia coli and serodiagnostic application. Arthritis Rheum (1988) 1.12
Wild-type levels of pregenomic RNA and replication but reduced pre-C RNA and e-antigen synthesis of hepatitis B virus with C(1653) --> T, A(1762) --> T and G(1764) --> A mutations in the core promoter. J Gen Virol (1998) 1.11
Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G-->A hypermutation. Virology (1997) 1.11
Prevalence and type of pre-C HBV mutants in anti-HBe positive carriers with chronic liver disease in a highly endemic area. Virology (1991) 1.10
Detailed characterization of the binding site of the lipoprotein lipase-specific monoclonal antibody 5D2. J Lipid Res (1998) 1.09
Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology (2000) 1.09
Duck hepatitis B virus expresses a regulatory HBx-like protein from a hidden open reading frame. J Virol (2001) 1.08
Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation. Hepatology (1996) 1.05
Cloning and expression of antigenic epitopes of the human 68-kDa (U1) ribonucleoprotein antigen in Escherichia coli. Biotechniques (1991) 1.05
Splice variants of the nuclear dot-associated Sp100 protein contain homologies to HMG-1 and a human nuclear phosphoprotein-box motif. J Cell Sci (1999) 1.05
Human hepatic triglyceride lipase: cDNA cloning, amino acid sequence and expression in a cultured cell line. Differentiation (1987) 1.03
Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology (1997) 1.03
Interrupted replication of hepatitis B virus in liver tissue of HBsAg carriers with hepatocellular carcinoma. Virology (1988) 1.02
The RNA-binding protein La contributes to cell proliferation and CCND1 expression. Oncogene (2010) 1.02
Cellular localization, expression, and structure of the nuclear dot protein 52. J Cell Biol (1997) 1.02
Autoantibodies against "nuclear dots" in primary biliary cirrhosis. Semin Liver Dis (1997) 1.01
Latency and reactivation of a precore mutant hepatitis B virus in a chronically infected patient. J Hepatol (1990) 1.01
Immunization with recombinant woodchuck hepatitis virus nucleocapsid antigen or hepatitis B virus nucleocapsid antigen protects woodchucks from woodchuck hepatitis virus infection. Vaccine (1993) 1.00
Construction of a plasmid for expression of foreign epitopes as fusion proteins with subunit B of Escherichia coli heat-labile enterotoxin. Infect Immun (1989) 1.00